Alternative applications for immunotherapy studies involving microfluidics have included a setup that functioned to mimic the drug toxicity-induced pulmonary oedema that is seen in cancer patients after IL-2 treatment (Fig. 4A).69 The platform hosted alveolar epithelial cells exposed to air flow and interfaced with an IL-2 perfused endothelial cell compartment. Here, IL2 is linked to cancer.